What is the recommended starting dose of intramuscular testosterone cypionate for adult women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testosterone Cypionate Starting Dose for Women (IM)

Start intramuscular testosterone cypionate at 50 mg weekly for adult women, which is the lower end of the evidence-based range and minimizes the risk of supraphysiologic levels while allowing for effective masculinization. 1

Recommended Starting Dose

  • The guideline-recommended starting dose for injectable testosterone enanthate or cypionate is 50-100 mg weekly via intramuscular injection. 1

  • Weekly dosing of 50-100 mg provides more stable testosterone levels compared to biweekly administration (100-200 mg every 2 weeks), reducing fluctuations that contribute to adverse effects. 1

  • In transgender patients specifically, starting at the lower end (50 mg weekly) and titrating upward is supported by recent evidence showing that higher starting doses often lead to supraphysiologic levels. 2, 3

Target Testosterone Levels

  • Aim for serum total testosterone in the physiologic male range of 300-1,000 ng/dL, with mid-normal values of 450-600 ng/dL preferred to optimize clinical response while minimizing adverse effects. 1

  • Measure testosterone levels 2-3 months after treatment initiation or any dose change, checking midway between injections to capture representative values. 1

Administration Considerations

  • Testosterone cypionate can be self-administered in the anterolateral thigh or given by another person in the gluteal region using a 21-23 gauge, 1-1.5 inch needle. 1

  • Subcutaneous injection is an effective and well-tolerated alternative to intramuscular administration, achieving therapeutic testosterone levels equivalent to IM with doses of 50-150 mg weekly across a wide BMI range. 3, 4, 5

  • Among patients who switched from IM to subcutaneous administration, all 22 patients in one study had a mild or marked preference for subcutaneous injections, with none preferring IM. 3

Dose Titration Strategy

  • If serum testosterone remains below target range (300-1,000 ng/dL) at 2-3 months, increase the dose incrementally by 25 mg weekly. 1, 3

  • The typical effective dose range is 50-150 mg weekly, with most patients achieving therapeutic levels at 75-80 mg weekly. 3

  • Once stable levels are achieved, monitor testosterone every 6-12 months along with hematocrit/hemoglobin, as erythrocytosis occurs in up to 43.8% of patients on injectable testosterone. 1

Common Pitfalls to Avoid

  • Do not start at doses higher than 100 mg weekly, as recent evidence suggests guideline-recommended starting doses of 5-30 mg every 2 weeks (equivalent to 2.5-15 mg weekly) may already be too high and lead to supraphysiologic levels. 2

  • Avoid biweekly dosing (100-200 mg every 2 weeks) in favor of weekly administration, as the former creates greater fluctuation in testosterone levels and increases the risk of erythrocytosis and other adverse effects. 1

  • Do not forget to prescribe necessary supplies: 18-gauge needles for drawing, 21-23 gauge 1-1.5 inch needles for injection, 1-3 mL syringes, alcohol prep pads, and a sharps container. 1

  • Monitor for erythrocytosis at every visit, as injectable formulations carry significantly higher risk (43.8%) compared to transdermal preparations (15.4%), and this risk is dose-dependent. 1

References

Guideline

Testosterone Replacement Therapy Dosing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

The Use of Injectable Estradiol in Transgender and Gender Diverse Adults: A Scoping Review of Dose and Serum Estradiol Levels.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024

Research

Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.